Table 2.
SARS-CoV-2 seroprevalence in children enrolled in the Alliance for Maternal and Newborn Health Improvement (AMANHI)-COVID-19 study cohort (n = 1097)
| Seroprevalence in children | Baseline survey | Follow-up survey |
|---|---|---|
|
Sero-samples processed % (95% CIs)*
|
n = 1097
|
n = 1063
|
|
|
18.4 (16.1-20.7) |
57.4(54.3-60.3) |
|
Child gender % (95% CIs)*
|
|
|
|
Males
|
n = 565
|
n = 545
|
|
|
17.1 (13.9-20.2) |
57.1 (52.8-61.0) |
|
Females
|
n = 532
|
n = 518
|
|
|
19.8 (16.5-23.1) |
57.6 (53.2-61.7) |
|
Child age, months % (95% CIs) ᵻ by age
|
|
|
|
24-36
|
n = 340
|
n = 86
|
|
|
17.4 (13.5-21.6) |
51.0 (39.9-61.6) |
|
37-48
|
n = 246
|
n = 398
|
|
|
19.6 (14.9-24.7) |
54.6 (49.6-59.4) |
|
≥49
|
n = 511
|
n = 579
|
| 18.7 (15.5-22.1) | 60.1 (55.9-63.9) |
*Adjusted by kit accuracy using Bayesian estimation with sensitivity = 1 and specificity = 0.998 (provided by the kit manufacturer).